JPMorgan Chase & Co. Issues Positive Forecast for Protagonist Therapeutics (NASDAQ:PTGX) Stock Price

Protagonist Therapeutics (NASDAQ:PTGX) had its price objective increased by JPMorgan Chase & Co. from $95.00 to $106.00 in a research note released on Thursday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other research analysts also recently commented on the company. Johnson Rice reaffirmed a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday. HC Wainwright increased their price objective on shares of Protagonist Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Citigroup boosted their target price on shares of Protagonist Therapeutics from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday. The Goldman Sachs Group upped their price target on shares of Protagonist Therapeutics from $65.00 to $95.00 and gave the stock a “neutral” rating in a report on Tuesday, March 3rd. Finally, Truist Financial increased their price target on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $107.31.

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock opened at $101.68 on Thursday. The firm has a market cap of $6.49 billion, a PE ratio of -49.60 and a beta of 2.23. The stock’s fifty day moving average price is $86.80 and its two-hundred day moving average price is $80.59. Protagonist Therapeutics has a one year low of $39.60 and a one year high of $105.69.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). The company had revenue of $7.44 million for the quarter, compared to the consensus estimate of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. Sell-side analysts expect that Protagonist Therapeutics will post 2.43 earnings per share for the current fiscal year.

Insider Transactions at Protagonist Therapeutics

In other news, CFO Asif Ali sold 46,203 shares of the stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $83.13, for a total value of $3,840,855.39. Following the completion of the transaction, the chief financial officer owned 60,320 shares of the company’s stock, valued at approximately $5,014,401.60. This represents a 43.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Arturo Md Molina sold 13,151 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $82.42, for a total transaction of $1,083,905.42. Following the completion of the sale, the insider owned 84,115 shares in the company, valued at approximately $6,932,758.30. The trade was a 13.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 203,167 shares of company stock valued at $16,889,199. Company insiders own 4.90% of the company’s stock.

Hedge Funds Weigh In On Protagonist Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC boosted its position in Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after buying an additional 156 shares in the last quarter. Greenline Wealth Management LLC acquired a new position in shares of Protagonist Therapeutics during the fourth quarter worth $27,000. Salomon & Ludwin LLC bought a new position in shares of Protagonist Therapeutics in the 3rd quarter valued at $29,000. EverSource Wealth Advisors LLC lifted its stake in shares of Protagonist Therapeutics by 138.9% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after acquiring an additional 314 shares during the last quarter. Finally, Abich Financial Wealth Management LLC acquired a new stake in shares of Protagonist Therapeutics during the 3rd quarter valued at $62,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: FDA approval and commercial terms: Johnson & Johnson’s U.S. FDA approval of ICOTYDE—an oral IL‑23R targeted peptide developed with Protagonist—triggered a $50 million milestone payment to Protagonist and makes the company eligible for 6–10% royalties plus up to $580 million in future milestones, creating a clear near‑ and long‑term revenue path tied to J&J’s commercialization. AccessWire: FDA approval and deal terms
• Positive Sentiment: Major analyst upgrades/price‑target lifts: Several firms raised targets and reiterated positive ratings today—Citigroup to $125 (Buy), Barclays to $119 (Overweight), Leerink to $110 (Outperform), and JPMorgan to $106 (Overweight)—signaling broad Wall Street support and further buying interest. (See links for coverage.) Benzinga: analyst coverage TickerReport: JPMorgan note
• Positive Sentiment: Wall Street commentary: Coverage highlights that J&J’s approval should create “significant value” for Protagonist via milestones and royalties, reinforcing the market narrative that the approval is transformational for PTGX. MSN: Wall Street reaction
• Positive Sentiment: Industry impact commentary: Media coverage frames Protagonist’s first approval as disruptive to larger immunology incumbents, supporting investor expectations of meaningful market share and pricing power if J&J’s launch gains traction. BioSpace: market impact
• Neutral Sentiment: Conference call/transcript and investor materials are available: Protagonist and partners provided conference/webcast materials and a transcript discussing the approval and clinical data; useful for investors wanting primary‑source detail on safety, efficacy, and commercial strategy. Seeking Alpha: transcript Seeking Alpha: slideshow
• Negative Sentiment: Commercial and timing risk: while the approval creates revenue pathways, Protagonist’s near‑term cash flow depends on J&J’s successful launch, market uptake timing, and royalty cadence—factors outside Protagonist’s direct control that could delay or limit realized revenue. AccessWire: deal structure & royalties

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.